SCHEMBL628550

SCHEMBL628550

O=[N+]([O-])c1c(Cl)nc(Cl)nc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
TSHR P16473 3/20 0.41
MAPT P10636 3/20 0.38
ALOX15 P16050 1/20 0.35
NPC1 O15118 2/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
TLR9 Q9NR96 2/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 1/20 0.32
XBP1 P17861 1/20 0.32
CYP3A4 P08684 1/20 0.32
OPRK1 P41145 2/20 0.32
KMT2A Q03164 2/20 0.32
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16297625 0.84 KMT2A (0.35) ALDH1A1TSHRMAPTOPRK1KMT2A
SCHEMBL2459982 0.84 MAPT (0.35) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL56358 0.84 MAPT (0.50) ALDH1A1TSHRMAPTKMT2ATDP1
SCHEMBL29978776 0.84 MAPT (0.35) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL18770821 0.82 ALDH1A1 (0.39) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL9871854 0.82 ALDH1A1 (0.39) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL12647914 0.80 TSHR (0.38) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL14135692 0.80 TSHR (0.38) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL1123974 0.80 MAPT (0.39) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL15222159 0.80 MAPT (0.34) ALDH1A1TSHRMAPTKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009097490-A1 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-08-06 WO claimed
US-20090192176-A1 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-30 US claimed
US-20260146049-A1 SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2026-05-28 US disclosed
EP-4674481-A2 CD73 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2026-01-07 EP disclosed
US-20260001880-A1 Bicyclic DGK Inhibitors INCYTE CORPORATION 2026-01-01 US disclosed
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF ILDONG PHARMACEUTICAL CO LTD (KR) 2025-12-25 US disclosed
US-20250368677-A1 CD73 INHIBITORS ORIC PHARMACEUTICALS INC (US) 2025-12-04 US disclosed
US-20250333424-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2025-10-30 US disclosed
EP-3787635-B1 CD73 INHIBITORS ORIC PHARMACEUTICALS INC (US) 2025-09-17 EP disclosed
EP-3938340-B1 HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS COLLABORATIVE MEDICINAL DEV LLC (US) 2025-07-09 EP disclosed
WO-2025122545-A1 TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS INCYTE CORPORATION (US) 2025-06-12 WO disclosed
US-4204056-A Process and intermediates for preparing fiber-reactive phthalocyanine dyes CASSELLA AKTIENGESELLSCHAFT (DE) 1980-05-20 US disclosed
US-4191686-A FROM SULFONYL HALIDE SUBSTITUTED PARENT BY AMIDATION WITH AROMATIC DIAMINE, DIAZOTIZING, COUPLING TO KETO SUCCINIC ESTER, CYCLIZING, COUPLING TO REACTIVE MOIETY CASSELLA AKTIENGESELLSCHAFT (DE) 1980-03-04 US disclosed
EP-0001614-A1 Water-soluble, fibre-reactive, green azo-phthalocyanine dyestuffs, their preparation and their application, as well as the phthalocyanine pyrazolone intermediates and their preparation CASSELLA Aktiengesellschaft (DE) 1979-05-02 EP disclosed
EP-0001629-A1 Water-soluble, fibre-reactive, green azo-phthalocyanine dyestuffs, their preparation and their use CASSELLA Aktiengesellschaft (DE) 1979-05-02 EP disclosed
US-4065446-A Reactive dyestuffs containing urea alkylene linkage between chromophore and reactive radical BAYER AKTIENGESELLSCHAFT (DT) 1977-12-27 US disclosed
US-4055411-A 5-NITRO-PYRIMIDINES CIBA-GEIGY CORPORATION (US) 1977-10-25 US disclosed
US-4014677-A HERBICIDES CIBA-GEIGY CORPORATION (US) 1977-03-29 US disclosed
US-3969101-A 4,6-DIAMINO-5-NITRO-2-ALKYLTHIO-PYRIMIDINES CIBA-GEIGY CORPORATION (US) 1976-07-13 US disclosed
US-3948914-A PLANT GROWTH REGULATORS CIBA-GEIGY CORPORATION (US) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192176-A1 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, PIK3CA, PIK3CD ALDH1A1 3052/4885TSHR 3706/4885MAPT 3265/4885
US-20250368677-A1 CD73 INHIBITORS ENTPD5, NT5E, ENTPD1 ALDH1A1 889/4885TSHR 3188/4885MAPT 1485/4885
US-20250333424-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, IRF3 ALDH1A1 3515/4885TSHR 4788/4885MAPT 2776/4885
US-20260001880-A1 Bicyclic DGK Inhibitors DGKA, DGKG, DGKZ ALDH1A1 2209/4885TSHR 2554/4885MAPT 4858/4885
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF GBA1, PIKFYVE, MAN2B1 ALDH1A1 3837/4885TSHR 3647/4885MAPT 3575/4885
US-20260146049-A1 SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER KRAS, NRAS, HRAS ALDH1A1 330/4885TSHR 1525/4885MAPT 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.